Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02475278 · ClinicalTrials.gov registry record · Phase 2
Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT02475278 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 50 participants.
The verdict
NCT02475278, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to collect serum samples to evaluate serologic assays and to establish proficiency panels for serologic assays used for assessment of post vaccination immune response after intramuscular (IM) vaccination with Norovirus GI.1/GII.4 bivalent virus-like particle (VLP) vaccine.
Interventions
- BIOLOGICAL NoV GI.1/GII.4 Bivalent VLP Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-02-26 |
| Est. Completion | 2015-09-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02475278
The ClinicalTrials.gov registry entry for NCT02475278 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NoV GI.1/GII.4 Bivalent VLP Vaccine is the first listed.
NCT02475278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02475278 about?
NCT02475278 is a clinical study titled "Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine". The purpose of this study is to collect serum samples to evaluate serologic assays and to establish proficiency panels for serologic assays used for assessment of post vaccination immune response after intramuscular (IM) vaccination with Norovirus GI.1/GII.4 bivalent virus-like particle (VLP) vaccin...
What is the current status of trial NCT02475278?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2015-02-26. Estimated completion is 2015-09-09.
What interventions are being tested in trial NCT02475278?
The interventions under investigation include: NoV GI.1/GII.4 Bivalent VLP Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02475278?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.